Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Chief Commercial Officer | July 12, 2019 | July 16, 2019 |
| GERON CORPGERN · Entity 4989 | EVP, Corp Strategy & CCO | June 10, 2024 | June 12, 2024 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Verastem, Inc.VSTM · Entity 5242 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date July 12, 2019 · Filed July 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.23 · Expires 2029-07-12 | Direct | 400,000 |
Reported balance
After 2019-07-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-12 · Grant · Acquired 400,000 · Balance 400,000 F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant.
GERON CORP
Report date June 10, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-10 · Exercise / conversion · Acquired 421,875 · Balance 421,875 Row 2 · 2024-06-10 · Sale · Disposed 421,875 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transacations at price ranging from $4.52 to $4.74, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each seperate price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2032-02-15 | Direct | 328,125 |
Reported balance
After 2024-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-10 · Exercise / conversion · Disposed 421,875 · Balance 328,125 F2: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022 (of which 421,875 shares were vested as of the exercise date), provided the optionee continues to provide services to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transacations at price ranging from $4.52 to $4.74, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each seperate price within the range set forth in this footnote.
F2: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022 (of which 421,875 shares were vested as of the exercise date), provided the optionee continues to provide services to the Company.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Verastem, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,666 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 36,000 · Balance 52,666 F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 22:18 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-066418 · tm2615478-2_4seq1.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,666 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 15, 2026 Filed May 15, 2026 21:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $15.86 | $0.00 |
DisclosureSEC source: 0001730703-26-000002 · wk-form4_1778881743.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:48 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001104659-25-053100 · tm2516118-7_4seq1.xml · derivative · entry 2 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:48 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-053100 · tm2516118-7_4seq1.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 19, 2025 Filed May 19, 2025 21:32 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0001549595-25-000078 · wk-form4_1747690358.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 20:48 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $24.87 | $0.00 |
DisclosureSEC source: 0001549595-24-000140 · wk-form4_1729111712.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-10-14 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning November 15, 2024, until the option is fully vested on October 15, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:31 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001104659-24-073609 · tm2417704-5_4seq1.xml · derivative · entry 2 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-18 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:31 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073609 · tm2417704-5_4seq1.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 F1 · shares: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Option (right to buy) · Derivative | 421,875 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000950170-24-072418 · ownership.xml · derivative · entry 3 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,125 Underlying: Common Stock · 421,875 shares Expires 2032-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022 (of which 421,875 shares were vested as of the exercise date), provided the optionee continues to provide services to the Company. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 421,875 | $4.65 | $1,959,609.38 |
DisclosureSEC source: 0000950170-24-072418 · ownership.xml · nonDerivative · entry 2 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transacations at price ranging from $4.52 to $4.74, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each seperate price within the range set forth in this footnote. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 421,875 | $1.06 | $447,187.50 |
DisclosureSEC source: 0000950170-24-072418 · ownership.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:10 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950170-24-070626 · ownership.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-12-01 F1 · derivative.exercise_date: Performance-based stock option granted on December 2, 2019 and vested in full on June 6, 2024 upon approval of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:10 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001415889-24-004105 · form4-02162024_090237.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, CORP STRATEGY & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 14, 2024, provided the optionee continues to provide service to the Company. Read SEC document |
| June 30, 2023 Filed Jul 1, 2023 01:18 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 7,567 | $2.04 | $15,436.68 |
DisclosureSEC source: 0001062993-23-014270 · form4.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,783 F1 · shares: The reporting person is voluntarily reporting the acquisition of 7,567 shares of the Issuer's common stock pursuant to the Geron Corporation 2014 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 3, 2023 through June 30, 2023. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 3, 2023. F3 · balance_after: The total number of securities beneficially owned of 60,783 shares represents the aggregate number of shares of Geron common stock purchased under the ESPP. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:34 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-23-061424 · tm2315836-6_4seq1.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-05-15 F1 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2023 to April, 2024 and the last installment shall vest on the earlier of (i) the day before the 2024 Annual Meeting of Stockholders is held or (ii) May 31, 2024, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 00:18 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 625,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001062993-23-004902 · form4.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 22, 2023, provided the optionee continues to provide services to the Company. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 01:55 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 6,021 | $1.11 | $6,683.31 |
DisclosureSEC source: 0001062993-23-000093 · form4.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,216 F1 · shares: The reporting person is voluntarily reporting the acquisition of 6,021 shares of the Issuer's common stock pursuant to the Geron Corporation 2014 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2022 through December 30, 2022 for the 12 month offering period beginning January 3, 2022. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 3, 2022. F3 · balance_after: The total number of securities beneficially owned of 53,216 shares represents the aggregate number of shares of Geron common stock purchased under the ESPP. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 20:09 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 163,185 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001104659-22-110922 · tm2228716-2_4seq1.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,185 Underlying: Common Stock · 163,185 shares Expires 2032-10-20 F1 · derivative.exercise_date: -125,000 of the stock options vest in twelve equal quarterly installments beginning each three successive month period following October 20, 2022 (the "Option Grant Date") until the third anniversary of the Option Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest). 38,185 of the stock options vest in eight equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from October, 2022 to May, 2023. The options vest provided the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 30, 2022 Filed Jul 2, 2022 01:25 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 13,062 | $1.11 | $14,498.82 |
DisclosureSEC source: 0001062993-22-015794 · form4.xml · nonDerivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,195 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Geron Corporation. 2014 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 3, 2022 through June 30, 2022. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 3, 2022. F3 · balance_after: The total securities beneficially owned 47,195 shares includes previous purchases under the ESPP. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:05 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001062993-22-005005 · form4.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022, provided the optionee continues to provide services to the Company. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 00:43 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0000886744-21-000014 · edgar.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 2, 2021, provided the optionee continues to provide services to the Company. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:22 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000886744-19-000076 · edgar.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · EVP, Corp Strategy & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2029-12-01 F1 · derivative.exercise_date: This option vests as follows: 87,500 shares on June 2, 2020, the remaining 612,500 shares in a series of 42 equal monthly installments commencing June 2, 2020, provided the optionee continues to provide services to the Company. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 20:59 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 400,000 | $0.23 Strike: $0.23 | $92,800.00 |
DisclosureSEC source: 0001213900-19-012873 · ownership.xml · derivative · entry 1 Kapur Anil · CIK 0001730703 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.